On 7 June 2018, the Agreement between the Kingdom of the Netherlands and the European Medicines Agency on the hosting of the European Medicines Agency was published in the Dutch Treaty Series.

The object and purpose of the agreement is to implement Protocol No 7 on the Privileges and Immunities of the European Union and to regulate other matters relating to or arising out of the establishment and the proper and continuous functioning of the EMA in the Netherlands. The agreement creates, among others, conditions for the stability and independence of the EMA and facilitates its smooth and efficient functioning (Article 2).

The agreement includes Articles on:

  • The legal status of the EMA (Article 3).
  • Matters relating to the EMA’s premises (Articles 4 and 6-9).
  • The application of Protocol No 7 (Article 5).
  • Official communications (Article 10).
  • The absence of restrictions for financial assets (Article 11).
  • Funds, assets and other property (Article 12).
  • Fiscal and customs treatment of the EMA (Article 13).
  • Exemption from import and export restrictions (Article 14).
  • Matters relating to the EMA’s staff members (Articles 15-23).
  • Waiver of immunities (Article 24).
  • Formal provisions (Articles 25-30).

The agreement came into force on 1 June 2018.

A prior version of this post was originally published by the same author in Practical Law – Life Sciences, June 2018 Issue (Thomson Reuters).

Print Friendly